SHINGRIX: Supply Update
The accelerated adoption of SHINGRIX has led to an unprecedented level of demand.
Healthcare professionals have adopted SHINGRIX and are now vaccinating against shingles at a much higher rate than in previous years.
Supplying the US market remains our highest priority, and we are committed to increasing and accelerating SHINGRIX supply. For 2019, we plan to bring significantly more doses to the US compared to 2018.
GSK plans to consistently release large shipments of doses into the marketplace 2 times a month starting in December of 2018.
- As healthcare professionals are vaccinating with SHINGRIX at an unprecedented rate, ordering limits and allocations should still be expected and individual customer resupply experiences will vary.
While demand still exceeds supply, the increased and consistent supply should provide reassurance that patients will have an opportunity to complete the 2-dose series within the 2-6 month dosing window.
There have been no manufacturing issues.
Thank you again for your partnership and commitment to protecting appropriate patients from shingles. Please do not hesitate to contact GSK with any further questions. You may reach us at 1-800-772-9292 or contact your GSK Vaccines Representative today.